CRISPR Therapeutics
Market Cap
US$5.9b
Last Updated
2020/09/24 06:01 UTC
Data Sources
Company Financials +
Executive Summary
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has CRISPR Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRSP has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.5%
CRSP
-0.8%
US Biotechs
-1.9%
US Market
1 Year Return
99.5%
CRSP
33.5%
US Biotechs
13.1%
US Market
Return vs Industry: CRSP exceeded the US Biotechs industry which returned 33.5% over the past year.
Return vs Market: CRSP exceeded the US Market which returned 13.1% over the past year.
Shareholder returns
| CRSP | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | -0.8% | -1.9% |
| 30 Day | -4.8% | 1.6% | -2.9% |
| 90 Day | 14.4% | -3.2% | 8.2% |
| 1 Year | 99.5%99.5% | 35.8%33.5% | 15.7%13.1% |
| 3 Year | 383.7%383.7% | 18.0%12.3% | 38.4%29.1% |
| 5 Year | n/a | 23.7%14.9% | 89.3%68.0% |
Price Volatility Vs. Market
How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
CRISPR Therapeutics AG's (NASDAQ:CRSP) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?1 month ago | Simply Wall St
Do Institutions Own CRISPR Therapeutics AG (NASDAQ:CRSP) Shares?1 month ago | Simply Wall St
Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging HigherValuation
Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?
253.65x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CRSP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CRSP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CRSP is poor value based on its PE Ratio (253.7x) compared to the US Biotechs industry average (21.6x).
PE vs Market: CRSP is poor value based on its PE Ratio (253.7x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: CRSP is poor value based on its PEG Ratio (13.8x)
Price to Book Ratio
PB vs Industry: CRSP is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.4x).
Next Steps
Future Growth
How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
18.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRSP's forecast earnings growth (18.4% per year) is above the savings rate (2.2%).
Earnings vs Market: CRSP's earnings (18.4% per year) are forecast to grow slower than the US market (23% per year).
High Growth Earnings: CRSP's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRSP's revenue (62.1% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CRSP's revenue (62.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRSP's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has CRISPR Therapeutics performed over the past 5 years?
0.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRSP has a large one-off gain of $16.0M impacting its June 30 2020 financial results.
Growing Profit Margin: CRSP became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by 0.4% per year.
Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: CRSP's Return on Equity (2.1%) is considered low.
Next Steps
Financial Health
How is CRISPR Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CRSP's short term assets ($965.6M) exceed its short term liabilities ($74.5M).
Long Term Liabilities: CRSP's short term assets ($965.6M) exceed its long term liabilities ($61.4M).
Debt to Equity History and Analysis
Debt Level: CRSP is debt free.
Reducing Debt: CRSP has no debt compared to 5 years ago when its debt to equity ratio was 110.5%.
Debt Coverage: CRSP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRSP has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRSP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Sam Kulkarni (41 yo)
2.75yrs
Tenure
US$16,265,732
Compensation
Dr. Samarth Kulkarni, also known as Sam, Ph.D., serves as an Independent Director at Repare Therapeutics Inc. since November 2019. Dr Kulkarni has been the Chief Executive Officer of CRISPR Therapeutics AG ...
CEO Compensation Analysis
Compensation vs Market: Sam's total compensation ($USD16.27M) is above average for companies of similar size in the US market ($USD7.43M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.75yrs | no data | 0.92% $ 54.9m | |
| CEO & Director | 2.75yrs | US$16.27m | 0.23% $ 13.7m | |
| Chief Financial Officer | 2.83yrs | US$4.04m | 0.00058% $ 34.5k | |
| Chief Operating Officer | 0.67yr | US$6.11m | 0.029% $ 1.7m | |
| General Counsel & Secretary | 3.25yrs | US$4.22m | 0% $ 0 | |
| Executive Vice President of Research & Development | 3.08yrs | US$6.01m | 0.048% $ 2.9m | |
| no data | no data | no data | ||
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data |
2.8yrs
Average Tenure
50.5yo
Average Age
Experienced Management: CRSP's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 2.75yrs | no data | 0.92% $ 54.9m | |
| CEO & Director | 2.75yrs | US$16.27m | 0.23% $ 13.7m | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Scientific Founder & Advisory Board Member | no data | no data | no data | |
| Independent Director | 5.42yrs | US$448.42k | 0.00038% $ 22.6k | |
| Independent Director | 6.83yrs | US$440.92k | 0% $ 0 | |
| Independent Director | 5.42yrs | US$451.92k | no data | |
| Head of Scientific Advisory Board | 2.58yrs | US$2.58m | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.25yrs | US$834.22k | 0% $ 0 |
2.8yrs
Average Tenure
53yo
Average Age
Experienced Board: CRSP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.
Top Shareholders
Company Information
CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CRISPR Therapeutics AG
- Ticker: CRSP
- Exchange: NasdaqGM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.943b
- Shares outstanding: 70.17m
- Website: https://www.crisprtx.com
Number of Employees
Location
- CRISPR Therapeutics AG
- Baarerstrasse 14
- Zug
- Zug
- 6300
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRSP | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Oct 2016 |
| 1CG | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Oct 2016 |
| 0VRQ | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Oct 2016 |
| CRSP N | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Oct 2016 |
Biography
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Pa ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/24 06:01 |
| End of Day Share Price | 2020/09/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.